β‑catenin inhibitors ICG‑001 and pyrvinium sensitize bortezomib‑resistant multiple myeloma cells to bortezomib

Wu,Cuicui

doi:10.3892/ol.2022.13326

β‑catenin inhibitors ICG‑001 and pyrvinium sensitize bortezomib‑resistant multiple myeloma cells to bortezomib

Authors:
- Cuicui Wu
View Affiliations

Affiliations: Department of Hematology, Yueyang Second People's Hospital, Yueyang, Hunan 414000, P.R. China
Published online on: May 12, 2022 https://doi.org/10.3892/ol.2022.13326
Article Number: 205
Copyright: © Wu . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although bortezomib (BTZ) displays efficacy in treating multiple myeloma (MM), BTZ resistance in MM patients has been reported. Meanwhile, treating BTZ resistant MM cells with β‑catenin inhibitors have demonstrated the ability to reserve BTZ resistance. Thus, the present study aimed to investigate the synergistic effect of the β‑catenin inhibitors, ICG‑001 and pyrvinium (PP), with BTZ in the treatment of BTZ‑resistant MM cells. Different concentrations of ICG‑001 (0‑32 µM) or PP (0‑32 nM) were used to treat the BTZ‑resistant RPMI‑8226 (RPMI‑8226BR) and BTZ‑resistant KMS‑11 (KMS‑11BR) cell lines, followed by a BTZ combination treatment. Subsequently, cell viability and apoptosis in these two cell lines were determined by CCK‑8 assay and flow cytometry, respectively. The proteins involved in the Wnt/β‑catenin signaling pathway were detected using western blotting. The Wnt/β‑catenin signaling pathway was activated in the RPMI‑8226BR and the KMS‑11BR cells. In addition, the cell viability of RPMI‑8226BR and KMS‑11BR cells were decreased following β‑catenin inhibitor (ICG‑001 and PP) treatment alone. Furthermore, the β‑catenin inhibitors, ICG‑001 and PP, plus BTZ combination treatment revealed a notable decrease in cell viability and a marked increase in cell apoptosis rate, compared with that in cells treated with ICG‑001, PP or BTZ alone in the RPMI‑8226BR and KMS‑11BR cell lines. In conclusion, the β‑catenin inhibitors, ICG‑001 and PP not only increased apoptosis, but also sensitized BTZ‑resistant MM cells to BTZ, indicating their potential therapeutic application in MM.

View Figures

View References

1	Barwick BG, Gupta VA, Vertino PM and Boise LH: Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front Immunol. 10:11212019. View Article : Google Scholar
2	Kyle RA and Rajkumar SV: Multiple myeloma. Blood. 111:2962–2972. 2008. View Article : Google Scholar : PubMed/NCBI
3	Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, et al: The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer. 8:e0007342020. View Article : Google Scholar : PubMed/NCBI
4	Rajkumar SV: Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 93:981–1114. 2018. View Article : Google Scholar
5	Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, et al: Therapy for relapsed multiple myeloma: Guidelines from the mayo stratification for myeloma and risk-adapted therapy. Mayo Clin Proc. 92:578–598. 2017. View Article : Google Scholar
6	Scott K, Hayden PJ, Will A, Wheatley K and Coyne I: Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 4:CD0108162016.PubMed/NCBI
7	Tibullo D, Giallongo C, Romano A, Vicario N, Barbato A, Puglisi F, Parenti R, Amorini AM, Wissam Saab M, Tavazzi B, et al: Mitochondrial functions, energy metabolism and protein glycosylation are interconnected processes mediating resistance to bortezomib in multiple myeloma cells. Biomolecules. 10:6962020. View Article : Google Scholar
8	Zaal EA, Wu W, Jansen G, Zweegman S, Cloos J and Berkers CR: Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer Metab. 5:72017. View Article : Google Scholar : PubMed/NCBI
9	Robak P, Drozdz I, Szemraj J and Robak T: Drug resistance in multiple myeloma. Cancer Treat Rev. 70:199–208. 2018. View Article : Google Scholar : PubMed/NCBI
10	Spaan I, Raymakers RA, van de Stolpe A and Peperzak V: Wnt signaling in multiple myeloma: A central player in disease with therapeutic potential. J Hematol Oncol. 11:672018. View Article : Google Scholar
11	Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK and Giles FJ: Wnt/beta-catenin pathway: Modulating anticancer immune response. J Hematol Oncol. 10:1012017. View Article : Google Scholar
12	Grigson ER, Ozerova M, Pisklakova A, Liu H, Sullivan DM and Nefedova Y: Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner. PLoS One. 10:e01176932015. View Article : Google Scholar : PubMed/NCBI
13	Xu F, Zhu Y, Lu Y, Yu Z, Zhong J, Li Y and Pan J: Anthelmintic pyrvinium pamoate blocks Wnt/β-catenin and induces apoptosis in multiple myeloma cells. Oncol Lett. 15:5871–5878. 2018.
14	Harada Y, Ishii I, Hatake K and Kasahara T: Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. Cancer Lett. 319:83–88. 2012. View Article : Google Scholar
15	Hirakawa T, Nasu K, Miyabe S, Kouji H, Katoh A, Uemura N and Narahara H: β-catenin signaling inhibitors ICG-001 and C-82 improve fibrosis in preclinical models of endometriosis. Sci Rep. 9:200562019. View Article : Google Scholar : PubMed/NCBI
16	Salem K, Brown CO, Schibler J and Goel A: Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity. Exp Hematol. 41:209–218. 2013. View Article : Google Scholar
17	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
18	Thibaudeau TA and Smith DM: A practical review of proteasome pharmacology. Pharmacol Rev. 71:170–197. 2019. View Article : Google Scholar : PubMed/NCBI
19	Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, et al: European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. 100:1254–1266. 2015. View Article : Google Scholar
20	Dai Y, Guo X and Yang C: Effect of bortezomib on proliferation and apoptosis of myeloma cells by activating Wnt/β-catenin signaling pathway. Oncol Lett. 20:1295–1299. 2020. View Article : Google Scholar
21	Guo N and Peng Z: MG132, a proteasome inhibitor, induces apoptosis in tumor cells. Asia Pac J Clin Oncol. 9:6–11. 2013. View Article : Google Scholar
22	Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, et al: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol. 28:4621–4629. 2010. View Article : Google Scholar
23	Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar
24	Taciak B, Pruszynska I, Kiraga L, Bialasek M and Krol M: Wnt signaling pathway in development and cancer. J Physiol Pharmacol. 69:2018.
25	Shi J, Liu Y, Xu X, Zhang W, Yu T, Jia J and Liu C: Deubiquitinase USP47/UBP64E regulates beta-Catenin ubiquitination and degradation and plays a positive role in Wnt signaling. Mol Cell Biol. 35:3301–3311. 2015. View Article : Google Scholar
26	Peterson LF, Sun H, Liu Y, Potu H, Kandarpa M, Ermann M, Courtney SM, Young M, Showalter HD, Sun D, et al: Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood. 125:3588–3597. 2015. View Article : Google Scholar : PubMed/NCBI
27	Su N, Wang P and Li Y: Role of Wnt/beta-catenin pathway in inducing autophagy and apoptosis in multiple myeloma cells. Oncol Lett. 12:4623–4629. 2016. View Article : Google Scholar
28	Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ and Orlowski RZ: Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 286:11009–11020. 2011. View Article : Google Scholar : PubMed/NCBI
29	Liu Y, Chen H, Zheng P, Zheng Y, Luo Q, Xie G, Ma Y and Shen L: ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population. J Exp Clin Cancer Res. 36:1252017. View Article : Google Scholar : PubMed/NCBI
30	Chan KC, Chan LS, Ip JC, Lo C, Yip TT, Ngan RK, Wong RN, Lo KW, Ng WT, Lee AW, et al: Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin. Sci Rep. 5:99792015. View Article : Google Scholar : PubMed/NCBI
31	Won HS, Lee KM, Oh JE, Nam EM and Lee KE: Inhibition of β-Catenin to overcome endocrine resistance in tamoxifen-resistant breast cancer cell line. PLoS One. 11:e01559832016. View Article : Google Scholar : PubMed/NCBI
32	Zhao Y, Masiello D, McMillian M, Nguyen C, Wu Y, Melendez E, Smbatyan G, Kida A, He Y, Teo JL and Kahn M: CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells. Oncogene. 35:3705–3717. 2016. View Article : Google Scholar : PubMed/NCBI
33	Zhang C, Zhang Z, Zhang S, Wang W and Hu P: Targeting of Wnt/β-Catenin by anthelmintic drug pyrvinium enhances sensitivity of ovarian cancer cells to chemotherapy. Med Sci Monit. 23:266–275. 2017. View Article : Google Scholar
34	Cui L, Zhao J and Liu J: Pyrvinium sensitizes clear cell renal cell carcinoma response to chemotherapy via Casein Kinase 1alpha-dependent inhibition of Wnt/β-Catenin. Am J Med Sci. 355:274–280. 2018. View Article : Google Scholar
35	Feng J, Jiang W, Liu Y, Huang W, Hu K, Li K, Chen J, Ma C, Sun Z and Pang X: Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer. Biochem Pharmacol. 177:1139602020. View Article : Google Scholar
36	Dattilo R, Mottini C, Camera E, Lamolinara A, Auslander N, Doglioni G, Muscolini M, Tang W, Planque M, Ercolani C, et al: Pyrvinium pamoate induces death of triple-negative breast cancer stem-like cells and reduces metastases through effects on lipid anabolism. Cancer Res. 80:4087–4102. 2020. View Article : Google Scholar : PubMed/NCBI
37	Yu DH, Macdonald J, Liu G, Lee AS, Ly M, Davis T, Ke N, Zhou D, Wong-Staal F and Li QX: Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. PLoS One. 3:e39512008. View Article : Google Scholar : PubMed/NCBI